Eli Lilly and Company $LLY Stake Reduced by First American Trust FSB

First American Trust FSB lowered its stake in Eli Lilly and Company (NYSE:LLY) by 10.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 27,732 shares of the company’s stock after selling 3,254 shares during the quarter. Eli Lilly and Company accounts for 1.7% of First American Trust FSB’s portfolio, making the stock its 10th biggest position. First American Trust FSB’s holdings in Eli Lilly and Company were worth $21,619,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company during the 1st quarter valued at $27,000. Financial Gravity Companies Inc. bought a new position in shares of Eli Lilly and Company during the second quarter valued at about $31,000. Blume Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares during the period. IMG Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company in the second quarter worth about $35,000. Finally, TD Capital Management LLC grew its stake in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on LLY shares. Daiwa Capital Markets increased their price objective on Eli Lilly and Company from $700.00 to $940.00 in a report on Monday, November 10th. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research note on Monday, November 10th. Berenberg Bank reissued a “hold” rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,015.11.

Eli Lilly and Company Price Performance

LLY opened at $1,023.32 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market cap of $967.43 billion, a price-to-earnings ratio of 66.88, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The stock has a fifty day simple moving average of $832.59 and a two-hundred day simple moving average of $780.91. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,033.62.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the company earned $1.18 earnings per share. The business’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.